SCHEMBL6853176

SCHEMBL6853176

CC[Si](CC)(CC)OC1C(=O)N(C(=O)OCCOC)C1c1cccs1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.46
GAA P10253 2/20 0.44
ALDH1A1 P00352 4/20 0.43
SMN1; SMN2 Q16637 3/20 0.42
NPSR1 Q6W5P4 3/20 0.42
HPGD P15428 3/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
CASP1 P29466 2/20 0.42
CASP7 P55210 2/20 0.42
MAPT P10636 2/20 0.42
ADORA2B P29275 1/20 0.38
APOBEC3A P31941 1/20 0.38
APOBEC3G Q9HC16 1/20 0.38
PKM P14618 1/20 0.38
LMNA P02545 4/20 0.37
KDM4E B2RXH2 2/20 0.37
HSD17B10 Q99714 2/20 0.37
HTT P42858 3/20 0.37
POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6853174 1.00 L3MBTL1 (0.46) L3MBTL1GAAALDH1A1SMN1; SMN2NPSR1
SCHEMBL6853180 1.00 L3MBTL1 (0.46) L3MBTL1GAAALDH1A1SMN1; SMN2NPSR1
SCHEMBL6858758 0.90 PKM (0.46) ALDH1A1NPSR1HPGDMEN1KMT2A
SCHEMBL6858753 0.90 PKM (0.46) ALDH1A1NPSR1HPGDMEN1KMT2A
SCHEMBL6858762 0.90 PKM (0.46) ALDH1A1NPSR1HPGDMEN1KMT2A
SCHEMBL6860096 0.90 LMNA (0.44) L3MBTL1ALDH1A1SMN1; SMN2NPSR1HPGD
SCHEMBL6860103 0.90 LMNA (0.44) L3MBTL1ALDH1A1SMN1; SMN2NPSR1HPGD
SCHEMBL6860099 0.90 LMNA (0.44) L3MBTL1ALDH1A1SMN1; SMN2NPSR1HPGD
SCHEMBL6858798 0.87 ADORA2B (0.36) L3MBTL1ALDH1A1SMN1; SMN2NPSR1HPGD
SCHEMBL6858791 0.87 ADORA2B (0.36) L3MBTL1ALDH1A1SMN1; SMN2NPSR1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6794523-B2 ANTICANCER AGENTS, ANTITUMOR AGENTS; LEUKEMIA FLORIDA STATE UNIVERSITY 2004-09-21 US disclosed
US-20030065200-A1 Anticancer agents, antitumor agents; leukemia FLORIDA STATE UNIVERSITY 2003-04-03 US disclosed
US-6018073-A Tricyclic taxanes having an alkoxy, alkenoxy or aryloxy substituted side-chain and pharmaceutical compositions containing them FLORIDA STATE UNIVERSITY (US) 2000-01-25 US disclosed
US-5739362-A ANTILEUKEMIA, ANTITUMOR AGENTS FLORIDA STATE UNIVERSITY (US) 1998-04-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030065200-A1 Anticancer agents, antitumor agents; leukemia MCL1, BCL3, TOP2A L3MBTL1 486/4885GAA 716/4885ALDH1A1 932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.